Invest in Life
IVAO — reliable partner of investors, scientists, entrepreneurs and experts
in the world of biotechnology, pharmaceuticals and medicine
IVAO News
Get the most relevant news, establish new social connections and communicate with world-known experts.

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Samsung Biologics (KRX: 207940.KS) announced that it has reached an agreement with Biogen for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis’ growth outlook.

Alzheimer’s disease can remain undetected until it is too late to treat. Large-scale screening programs could help to detect early-stage disease, but current diagnostic methods are too cumbersome and expensive. A new study published to Frontiers is the first to identify formic acid as a sensitive urinary biomarker that can reveal early-stage Alzheimer’s disease, potentially paving the way for inexpensive and convenient disease screening.  

Database IVAO
The database presents the most promising opportunities for investing your capital.